266 related articles for article (PubMed ID: 21179009)
21. Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression.
Clark KR; Sferra TJ; Lo W; Qu G; Chen R; Johnson PR
J Drug Target; 1999 Dec; 7(4):269-83. PubMed ID: 10682906
[TBL] [Abstract][Full Text] [Related]
22. Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.
Hirsch ML; Wolf SJ; Samulski RJ
Methods Mol Biol; 2016; 1382():21-39. PubMed ID: 26611576
[TBL] [Abstract][Full Text] [Related]
23. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.
Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL
Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800
[TBL] [Abstract][Full Text] [Related]
24. Design of shRNA and miRNA for Delivery to the CNS.
Toro Cabrera G; Mueller C
Methods Mol Biol; 2016; 1382():67-80. PubMed ID: 26611579
[TBL] [Abstract][Full Text] [Related]
25. Recombinant adeno-associated viral vectors in the nervous system.
Burger C; Nash K; Mandel RJ
Hum Gene Ther; 2005 Jul; 16(7):781-91. PubMed ID: 16000060
[TBL] [Abstract][Full Text] [Related]
26.
Batista AR; King OD; Reardon CP; Davis C; Shankaracharya ; Philip V; Gray-Edwards H; Aronin N; Lutz C; Landers J; Sena-Esteves M
Hum Gene Ther; 2020 Jan; 31(1-2):90-102. PubMed ID: 31696742
[TBL] [Abstract][Full Text] [Related]
27. A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.
Ferrand M; Galy A; Boisgerault F
Gene Ther; 2014 Sep; 21(9):828-39. PubMed ID: 25030611
[TBL] [Abstract][Full Text] [Related]
28. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
29. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.
Majowicz A; Maczuga P; Kwikkers KL; van der Marel S; van Logtenstein R; Petry H; van Deventer SJ; Konstantinova P; Ferreira V
J Gene Med; 2013; 15(6-7):219-32. PubMed ID: 23658149
[TBL] [Abstract][Full Text] [Related]
30. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
Qiao C; Yuan Z; Li J; He B; Zheng H; Mayer C; Li J; Xiao X
Gene Ther; 2011 Apr; 18(4):403-10. PubMed ID: 21150938
[TBL] [Abstract][Full Text] [Related]
31. Deletion of the B-B' and C-C' regions of inverted terminal repeats reduces rAAV productivity but increases transgene expression.
Zhou Q; Tian W; Liu C; Lian Z; Dong X; Wu X
Sci Rep; 2017 Jul; 7(1):5432. PubMed ID: 28710345
[TBL] [Abstract][Full Text] [Related]
32. Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity.
Guilbaud M; Devaux M; Couzinié C; Le Duff J; Toromanoff A; Vandamme C; Jaulin N; Gernoux G; Larcher T; Moullier P; Le Guiner C; Adjali O
Hum Gene Ther; 2019 Jul; 30(7):802-813. PubMed ID: 30808235
[TBL] [Abstract][Full Text] [Related]
33. Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation.
Winbanks CE; Beyer C; Qian H; Gregorevic P
PLoS One; 2012; 7(12):e51627. PubMed ID: 23251598
[TBL] [Abstract][Full Text] [Related]
34. Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice.
Fluri DA; Baba MD; Fussenegger M
BMC Biotechnol; 2007 Nov; 7():75. PubMed ID: 17986332
[TBL] [Abstract][Full Text] [Related]
35. Novel expression vectors enabling induction of gene expression by small-interfering RNAs and microRNAs.
Harel L; Gefen N; Carmi O; Orbach P; Einat P; Abitbol G
PLoS One; 2014; 9(12):e115327. PubMed ID: 25514749
[TBL] [Abstract][Full Text] [Related]
36. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors.
Recchia A; Perani L; Sartori D; Olgiati C; Mavilio F
Mol Ther; 2004 Oct; 10(4):660-70. PubMed ID: 15451450
[TBL] [Abstract][Full Text] [Related]
37. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
Koo T; Popplewell L; Athanasopoulos T; Dickson G
Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
[TBL] [Abstract][Full Text] [Related]
38. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.
Ren C; Kumar S; Shaw DR; Ponnazhagan S
Hum Gene Ther; 2005 Sep; 16(9):1047-57. PubMed ID: 16149903
[TBL] [Abstract][Full Text] [Related]
39. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain.
Aschauer DF; Kreuz S; Rumpel S
PLoS One; 2013; 8(9):e76310. PubMed ID: 24086725
[TBL] [Abstract][Full Text] [Related]
40. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
